BioAlliance Pharma announces the launch of Oravig® on the US market by its commercial partner, Strativa/Par Pharmaceutical
24 Aug, 2010
BioAlliance Pharma SA (Euronext Paris – BIO), a company dedicated to the supportive care and treatment of cancer patients, today announces the launch in the United States of Oravig® (known as Loramyc® in Europe) for the treatment of oropharyngeal candidiasis (OPC) in adults by its commercial partner, Strativa Pharmaceuticals, the proprietary products division of Par Pharmaceutical Companies, Inc. (NYSE:PRX).
With a US FDA approval in April 2010, BioAlliance Pharma is the first small medium-sized innovative French company to have access to the American market, the largest worldwide market.
Oravig® is already available on the US market. The national sales force meeting of Strativa is being held this week in the United States to prepare the promotion of the product to the prescribers.
«The US launch of Oravig® is the ultimate step of a process that confirms our expertise in development and registration of products at the international level. It represents a major achievement that will generate significant revenues for BioAlliance Pharma», declares Dominique Costantini, its CEO. « We are very confident in Strativa sales team’s commitment and know-how to ensure Oravig® success in the US, a product presenting a strong synergy with the product portfolio already commercialized by our US partner».